A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LA / leuprolide acetate

[Related PubMed/MEDLINE]
Total Number of Papers: 158
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LA  (>> Co-occurring Abbreviation)
Long Form:   leuprolide acetate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres. IVIVCs
2019 Treatment with depot leuprolide acetate in girls with idiopathic precocious puberty: What is the best parameter to decide the initial dose? BW, HPG, ICPP
2018 Administration of leuprolide acetate, a GnRH agonist, improves urodynamic parameters in ovariectomized rats. BP, GnRHR, ICI, NVC
2018 Anti-cancer effect of GV1001 for prostate cancer; function as a ligand of GnRHR. GnRHR, HPG, hTERT, PCa
2018 Changes in body composition and mRNA expression of ghrelin and lipoprotein lipase in rats treated with leuprolide acetate, a GnRH agonist. GnRH, LPL
2018 Dienogest Versus Leuprolide Acetate for Recurrent Pelvic Pain Following Laparoscopic Treatment of Endometriosis. DNG
2018 Neurological improvement in patients with chronic spinal cord injury treated with leuprolide acetate, an agonist of GnRH. ASIA, GnRH, SCI, SCIM
2018 Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. IM, LH, PD, PK, s.c
2018 Successes and failures of uterine leiomyoma drug discovery. GnRH, UFs
10  2017 Apoptosis of bovine granulosa cells: Intracellular pathways and differentiation. 3beta-HSD, GnRH, PLD
11  2017 The impact of postnatal leuprolide acetate treatment on reproductive characteristics in a rodent model of polycystic ovary syndrome. PostN, PostN L, PreN
12  2016 Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy. ISPOR, NETA
13  2016 Analysis of subsequent surgery rates among endometriosis patients who underwent surgery with and without concomitant leuprolide acetate therapy. HR
14  2016 Aqueous stability of leuprolide acetate: effect of temperature, dissolved oxygen, pH and complexation with beta-cyclodextrin. beta-CD, DSC, FTIR, PBS
15  2016 Fertility counseling and preservation practices in youth with lupus and vasculitis undergoing gonadotoxic therapy. PRs
16  2016 Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. ECM
17  2016 Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. ADT, GnRH
18  2016 Leuprolide Acetate Inhibits Spinal Cord Inflammatory Response in Experimental Autoimmune Encephalomyelitis by Suppressing NF-kappaB Activation. GnRH, NF
19  2016 Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. CPP, GnRHa, LH
20  2016 Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh. MCT, SPC, SPME
21  2015 Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. ADT
22  2015 Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? IL, MMP, TNF-alpha, VEGF
23  2014 Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer. PK
24  2014 GnRH agonists induce endometrial epithelial cell apoptosis via GRP78 down-regulation. DIGE
25  2013 In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. ---
26  2013 Theranekron for treatment of endometriosis in a rat model compared with medroxyprogesterone acetate and leuprolide acetate. MPA
27  2013 [Ulipristal acetate, 5mg: a new alternative]. SPRMs, UA
28  2012 Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. DNG
29  2012 Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. ER, PR
30  2012 Serum levels of antimullerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. AMH
31  2011 A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. PR
32  2011 Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. s.c
33  2011 [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study]. LHRHa, PSA, TNM
34  2010 Add-back therapy use and its impact on LA persistence in patients with endometriosis. GnRH-a, NA
35  2010 Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. BMD, VAS
36  2010 Do GnRH analogues directly affect human endometrial epithelial cell gene expression? cAMP, EREs, GA, GnRH, OPTN, PREs, PSAP, SNX7
37  2010 Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls. IL-1beta, VEGF
38  2010 Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. SHBG
39  2010 Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. ---
40  2010 Use of F 18-fluoro-D-glucose-positron emission tomography-computed tomography to localize a hilar cell tumor of the ovary. ---
41  2009 Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. ISFIs, PLGA
42  2009 Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. CPP, LHRH
43  2009 Microdose follicular flare: a viable alternative for normal-responding patients undergoing in vitro fertilization? ART, LL, MDF, OCP
44  2009 Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. ICSI, PR
45  2008 Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. AR, COH, Gn, GnRH, IR, LH, OHSS, PR
46  2008 Evaluation of the American version of the 30-item Endometriosis Health Profile (EHP-30). DMPA
47  2008 Leuprolide acetate reduces both in vivo and in vitro ovarian steroidogenesis in infertile women undergoing assisted reproduction. FF, GCC
48  2008 Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients. OC
49  2008 Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs. Ant
50  2007 Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. EEC, GnRHa, GnRHant
51  2007 Inhibition of cytochrome P-450 C17 enzyme by a GnRH agonist in ovarian follicles from gonadotropin-stimulated rats. eCG, GnRH, P450C17, StAR
52  2007 Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. BA, BB, dl-PLA
53  2007 Zinc-leuprolide complex: preparation, physicochemical characterization and release behaviour from in situ forming implant. DSC, FTIR, ISFI, XRD
54  2006 Effect of gonadotropin-releasing hormone agonist and antagonist on proliferation and apoptosis of human luteinized granulosa cells. ANT
55  2006 Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination. hCG, hMG, IUI, LH, LPD
56  2005 Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. AUC, ROC
57  2005 Gonadotropin-releasing hormone antagonist antide inhibits apoptosis of preovulatory follicle cells in rat ovary. Ant, EAFs, GnRH-a, PFs, POFs
58  2005 Leuprolide acetate suppresses pedophilic urges and arousability. ---
59  2005 Sleep, breathing, and menopause: the effect of fluctuating estrogen and progesterone on sleep and breathing in women. OSA, SDB
60  2004 Control of musth in an Asian elephant bull (Elephas maximus) using leuprolide acetate. ---
61  2004 Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. ---
62  2003 Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. ELISA, IL-1beta, VEGF
63  2003 Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. GnRH-a
64  2003 Steroidogenic acute regulatory protein in ovarian follicles of gonadotropin-stimulated rats is regulated by a gonadotropin-releasing hormone agonist. eCG, GnRH-a, P450scc, RT-PCR, StAR
65  2002 A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. RIA, SD
66  2002 Effects of a gonadotropin-releasing hormone agonist on rat ovarian follicle apoptosis: regulation by epidermal growth factor and the expression of Bcl-2-related genes. EGF, POF
67  2001 Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. GnRHa
68  2000 A case of atypical absence seizures induced by leuprolide acetate. ---
69  2000 Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program. COH, GnRH-a, LA depot
70  2000 Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? ---
71  1999 Incorporation of a GnRH agonist, leuprolide acetate, into regimens with exogenous gonadotropins to produce ovarian stimulation and ovulation in the nonpregnant squirrel monkey. FSH
72  1999 Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. GnRH-a
73  1999 Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. GnRH-a, OC
74  1999 Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. HAIR-AN
75  1999 The effect of pituitary desensitization on ovarian volume measurements prior to in-vitro fertilization. FSH, IVF
76  1999 [Comparison of endometrial histology and ultrastructure during different ovarian stimulation protocols in hamsters]. GnRH-a, PMSG
77  1998 Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. ER, GnRH, PCNA, PR
78  1998 Day 4 estradiol levels predict pregnancy success in women undergoing controlled ovarian hyperstimulation for IVF. COH
79  1998 Effects of Ringer's lactate, medroxyprogesterone acetate, gonadotropin-releasing hormone analogue and its diluent on the prevention of postsurgical adhesion formation in rat models. MPA, RL
80  1998 Induction of fertile estrus in bitches using a sustained-release formulation of a GnRH agonist (leuprolide acetate). ---
81  1997 Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. ---
82  1997 Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. 17-OHP, 17-Preg
83  1997 Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. CEE, MA
84  1997 Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. GnRH, i.v, IM, s.c
85  1997 Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. BMD
86  1997 Prematurely condensed chromosomes and meiotic abnormalities in unfertilized human oocytes after ovarian stimulation with and without gonadotropin-releasing hormone agonist. COH
87  1997 The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation. IVF, NETA
88  1997 [Regulation of follicular luteinization by an agonist of gonadotropin-releasing hormone (GnRH)]. GnRH
89  1996 A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. hMG, IVF, NETA
90  1996 A double-blind comparison of nafarelin and leuprolide acetate for down-regulation in IVF cycles. NAF
91  1996 A randomized clinical trial to evaluate the clinical effects of split- versus single-dose human menopausal gonadotropins in an assisted reproductive technology program. ART
92  1996 Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. CPA, OC, PCOD, SHBG
93  1996 Dose-response effect of depot leuprolide acetate on serum androgens in hirsute women. ---
94  1996 Effects of a gonadotropin-releasing hormone analog on rabbit ovarian function. NZW
95  1996 Evaluation of serum CA 125 concentrations as predictors of pregnancy with human in vitro fertilization. ---
96  1996 Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group. ---
97  1996 Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls. ---
98  1996 Pituitary response to early follicular-phase minidose gonadotropin releasing hormone agonist (GnRHa) therapy: evidence for a second flare. FSH, GnRHa
99  1996 Reversible suppression of pituitary-testicular function by a sustained-release formulation of a GnRH agonist (leuprolide acetate) in dogs. ---
100  1996 Use of medroxyprogesterone acetate in the prevention of postoperative adhesions. MPA